Crossmark

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12943-018-0777-1

Published Online: 2018-02-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wu, Shang-Gin

Shih, Jin-Yuan
More Information

Article History

Received: 31 October 2017

Accepted: 1 February 2018

First Online: 19 February 2018

Competing interests

: Jin-Yuan Shih has received speaking honoraria from AstraZeneca, Roche, Pfizer, Boehringer Ingelheim, Novartis, and Eli Lilly. Shang-Gin Wu has no conflicts of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.